In partnership with industry and government, Omico launched the pioneering initiative PrOSPeCT in July 2023, aimed at integrating comprehensive genomic profiling (CGP) into standard oncology care in Australia. To date, Omico has provided CGP to over 15,000 patients, of whom more than 1,600 have received matched therapies primarily through accelerated access to clinical trials. Professor David Thomas, CEO of Omico, talks about the work the institution does in this talk at RED 2024.